The Lymphoma and Leukemia Society Amended COVID-19 Registry


Participants in The Leukemia and Lymphoma Society (LLS) National Research Registry will be invited to participate in the LLS Covid-19 Registry to evaluate medical outcomes for people with blood cancer, who have been diagnosed with COVID-19, have received, or are planning to receive, a COVID-19 vaccination.

If you are or have been a blood cancer patient, please consider joining the Registry today, especially if you have been diagnosed with COVID-19 or if you have been vaccinated against COVID-19 or plan to be. Joining is safe, easy, and free. If you need assistance with joining the Registry, please call 1-855-244-8493 or visit the Michael Garil National Patient Registry page.

SparkCures ID 1155
Enrollment 1000 Patients
Trial Sponsors
  • Leukemia and Lymphoma Society
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • People with blood cancer already participating in The Lymphoma and Leukemia National Research Registry

Exclusion Criteria:

  • Unwilling or unable to receive COVID-19 vaccination

US Trial Locations

Please visit the page for historical site information.

View Centers